Advertisement
Corrigendum Free access | 10.1172/JCI23549C1
Find articles by Fischbach, G. in: JCI | PubMed | Google Scholar
Find articles by Fischbach, R. in: JCI | PubMed | Google Scholar
Published December 15, 2004 - More info
Human embryonic stem cells offer the promise of a new regenerative medicine in which damaged adult cells can be replaced with new cells. Research is needed to determine the most viable stem cell lines and reliable ways to promote the differentiation of pluripotent stem cells into specific cell types (neurons, muscle cells, etc.). To create new cell lines, it is necessary to destroy preimplantation blastocysts. This has led to an intense debate that threatens to limit embryonic stem cell research. The profound ethical issues raised call for informed, dispassionate debate.
Gerald D. Fischbach, Ruth L. Fischbach
Original citation: J. Clin. Invest.114:1364–1370 (2004). doi:10.1172/JCI23549
Citation for this erratum: J. Clin. Invest.114:1820 (2004). doi:10.1172/JCI23549C1
The definition of “totipotent” was incorrectly identified as “Cell committed to a specific lineage that is capable of giving rise to all types of differentiated cells and tissues, including extraembryonic tissues.” The correct definition is “Cell not committed to a specific lineage that is capable of giving rise to all types of differentiated cells and tissues, including extraembryonic tissues.”
Gerald D. Fischbach's corresponding address was incomplete. Address correspondence to: Gerald D. Fischbach, Department of Pharmacology, Dean of the Faculty of Medicine, Columbia University College of Physicians and Surgeons, P&S 2-401, 630 West 168th Street, New York, New York 10032, USA. Phone: (212) 305-2752; Fax: (212) 305-3617; E-mail: gdf@columbia.edu.